Drug Profile


Alternative Names: DAG for Injection; NSC-1323313; VAL-083

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator DelMar Pharmaceuticals
  • Developer DelMar Pharmaceuticals; Guangxi Wuzhou Pharmaceutical; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Ethylene glycols; Small molecules
  • Mechanism of Action Alkylating agents; Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Ovarian cancer; Medulloblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic myeloid leukaemia; Lung cancer

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Lung cancer
  • Phase II Glioblastoma
  • Clinical Phase Unknown Haematological malignancies; Solid tumours
  • Preclinical Medulloblastoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 05 Apr 2017 DelMar Pharmaceuticals plans a pivotal phase III trial for Glioblastoma (Second line therapy or greater)
  • 20 Jan 2017 DelMar Pharmaceuticals initiates enrolment in a phase II trial for Glioblastoma (Second-line therapy or greater, Recurrent, Late-stage disease) in USA (NCT02717962)
  • 14 Dec 2016 DelMar Pharmaceuticals receives patent allowance for dianhydrogalactitol in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top